In addition to the expected thrombocytopenia (which was manageable) due to the inhibition of BCL-XL, dose limiting neutropenia was observed which was believed to be caused by the inhibition of BCL-2 coupled with the effects caused by chemotherapy [127]. Here, BCL2L1 is linked to neutropenia.